Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study

American Heart Journal

Volumn 196, Issue , 2018, Pages 18-27

  Anyanwagu, Uchenna ^a   Mamza, Jil ^a   Donnelly, Richard ^a   Idris, Iskandar ^a  

^a Division of Medical Sciences Graduate Entry Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ADD ON THERAPY; ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; AGED; BODY MASS; COMBINATION DRUG THERAPY; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OVERWEIGHT; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED KINGDOM;

EID: 85034414401     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.10.003     Document Type: Article

References (31)

1. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:15 (2008), 1577–1589.
2. Ray, K.K., Seshasai, S.R.K., Wijesuriya, S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:9677 (2009), 1765–1772.
3. Diabetes Prevention Program Research Group, 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:9702 (2009), 1677–1686.
4. Dixon, L., Weiden, P., Delahanty, J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:4 (2000), 903–912.
5. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:1 (2015), 140–149.
6. Russell-Jones, D., Khan, R., Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 9:6 (2007), 799–812.
7. The Action to Control Cardiovascular risk in Diabetes Study Group, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
8. Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383:9933 (2014), 2008–2017.
9. Van Avendonk, M.W.J., Rutten, G.E.H., Insulin therapy in type 2 diabetes: what is the evidence?. Diabetes Obes Metab 11:5 (2009), 415–432.
10. Currie, C.J., Poole, C.D., Evans, M., et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 98:2 (2013), 668–677.
11. Roumie, C.L., Greevy, R.A., Grijalva, C.G., et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311:22 (2014), 2288–2296.
12. Colayco, D.C., Niu, F., McCombs, J.S., et al. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 34:1 (2011), 77–83.
13. Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ Res 114 (2014), 1788–1803, 10.1161/CIRCRESAHA.114.301958.
14. Okerson, T., Chilton, R., The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 30 (2012), e146–e155.
15. Monami, M., Cremasco, F., Lamanna, C., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res, 2011, 2011, 10.
16. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:4 (2016), 311–322, 10.1056/NEJMoa1603827 [Epub 2016 Jun 13].
17. Waldrop, G., Zhong, J., Peters, M., et al. Incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol 67:12 (2016), 1488–1489.
18. Blak, B.T., Thompson, M., Dattani, H., et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:4 (2011), 251–255.
19. Lewis, J.D., Schinnar, R., Bilker, W.B., et al. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16:4 (2007), 393–401.
20. Idris, I., Warren, G., Donnelly, R., Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 172 (2012), 1005–1011.
21. Anyanwagu, U., Mamza, J., Mehta, R., et al. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 102 (2016), 1581–1587.
22. StataCorp, Stata statistical software: release 13. 2013, StataCorp LP, College Station, TX.
23. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:19 (2016), 1834–1844.
24. Lind, M., Hirsch, I.B., Tuomilehto, J., et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, 351, 2015, h5364, 10.1136/bmj.h5364.
25. Ahrén, B., Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes 5 (2014), 40–51.
26. Mathieu, C., Rodbard, H.W., Cariou, B., et al. BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 16 (2014), 636–644.
27. Wolffenbuttel, B.H.R., Nauck, M.A., Shaginian, R., et al. Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs. insulin lispro TID added to titrated insulin glargin QD: the 4B study. Diabetologia 56:Suppl. 1 (2012-2013), A15–A16 S7 [61].
28. Ahren, B., Mathieu, C., Bader, G., et al. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia 57 (2014), 1304–1307.
29. Goto, A., Arah, O.A., Goto, M., et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ, 347, 2013, f4533.
30. Cho, E., Manson, J.E., Stampfer, M.J., et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 25:7 (2002), 1142–1148.
31. National Institute for Health and Care Excellence (NICE), Type 2 diabetes in adults: management. Available at https://www.nice.org.uk/guidance/ng2. (Accessed 13 December 2016)